Healthcare provider profile · identity verified

Jon Kevin Richter, MD

Family Practice · BRANSON, MO · NPI 1093710113

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Lisinopril	Lisinopril	367	97
Atorvastatin Calcium	Atorvastatin Calcium	366	115
Omeprazole	Omeprazole	322	79
Levothyroxine Sodium	Levothyroxine Sodium	267	66
Gabapentin	Gabapentin	234	67
Amlodipine Besylate	Amlodipine Besylate	216	63
Metformin Hcl	Metformin Hcl	197	50
Losartan Potassium	Losartan Potassium	163	44
Furosemide	Furosemide	141	41
Duloxetine Hcl	Duloxetine Hcl	139	31
Metoprolol Succinate	Metoprolol Succinate	134	33
Pantoprazole Sodium	Pantoprazole Sodium	124	31
Tamsulosin Hcl	Tamsulosin Hcl	120	34
Tramadol Hcl	Tramadol Hcl	108	29
Albuterol Sulfate Hfa	Albuterol Sulfate	104	43
Potassium Chloride	Potassium Chloride	95	28
Hydrochlorothiazide	Hydrochlorothiazide	89	21
Carvedilol	Carvedilol	84	30
Metoprolol Tartrate	Metoprolol Tartrate	83	26
Glipizide Er	Glipizide	82	19
Clopidogrel	Clopidogrel Bisulfate	78	23
Rosuvastatin Calcium	Rosuvastatin Calcium	78	17
Zolpidem Tartrate	Zolpidem Tartrate	78	18
Meloxicam	Meloxicam	71	23
Alprazolam	Alprazolam	61	12
Eliquis	Apixaban	61	13
Pravastatin Sodium	Pravastatin Sodium	55	12
Spironolactone	Spironolactone	55	15
Allopurinol	Allopurinol	51	15
Citalopram Hbr	Citalopram Hydrobromide	51	15
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	50	12
Fluticasone Propionate	Fluticasone Propionate	50	23
Escitalopram Oxalate	Escitalopram Oxalate	49	16
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	49	17
Prednisone	Prednisone	48	35
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	48	suppressed
Famotidine	Famotidine	45	15
Montelukast Sodium	Montelukast Sodium	44	13
Ventolin Hfa	Albuterol Sulfate	44	14
Alendronate Sodium	Alendronate Sodium	43	suppressed
Atenolol	Atenolol	41	11
Glipizide	Glipizide	41	12
Jardiance	Empagliflozin	41	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	41	16
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	40	13
Trazodone Hcl	Trazodone Hcl	40	13
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	38	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	38	32
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	37	13
Warfarin Sodium	Warfarin Sodium	37	11
Clonazepam	Clonazepam	36	suppressed
Estradiol	Estradiol	36	11
Xarelto	Rivaroxaban	34	suppressed
Hydralazine Hcl	Hydralazine Hcl	33	suppressed
Lorazepam	Lorazepam	32	suppressed
Metformin Hcl Er	Metformin Hcl	32	16
Tizanidine Hcl	Tizanidine Hcl	32	suppressed
Fenofibrate	Fenofibrate	29	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	29	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	27	suppressed
Incruse Ellipta	Umeclidinium Bromide	27	suppressed
Symbicort	Budesonide/Formoterol Fumarate	27	suppressed
Clonidine Hcl	Clonidine Hcl	26	suppressed
Diazepam	Diazepam	26	suppressed
Finasteride	Finasteride	26	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	26	suppressed
Ozempic	Semaglutide	26	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	26	suppressed
Spiriva Handihaler	Tiotropium Bromide	26	suppressed
Pregabalin	Pregabalin	25	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	24	suppressed
Cephalexin	Cephalexin	24	22
Donepezil Hcl	Donepezil Hcl	24	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	24	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	24	suppressed
Baclofen	Baclofen	21	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	21	17
Sucralfate	Sucralfate	21	suppressed
Lovastatin	Lovastatin	20	suppressed
Celecoxib	Celecoxib	19	suppressed
Simvastatin	Simvastatin	19	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	18	suppressed
Diclofenac Sodium	Diclofenac Sodium	18	suppressed
Propranolol Hcl	Propranolol Hcl	18	suppressed
Azithromycin	Azithromycin	17	15
Ondansetron Hcl	Ondansetron Hcl	17	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	17	15
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	16	16
Farxiga	Dapagliflozin Propanediol	16	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	16	suppressed
Myrbetriq	Mirabegron	16	suppressed
Bumetanide	Bumetanide	15	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	15	suppressed
Paroxetine Hcl	Paroxetine Hcl	15	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	14	suppressed
Promethazine Hcl	Promethazine Hcl	14	suppressed
Valsartan	Valsartan	14	suppressed
Acyclovir	Acyclovir	13	suppressed
Breo Ellipta	Fluticasone/Vilanterol	13	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	13	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	13	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	13	suppressed
Januvia	Sitagliptin Phosphate	13	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	13	12
Aripiprazole	Aripiprazole	12	suppressed
Bupropion Xl	Bupropion Hcl	12	suppressed
Memantine Hcl	Memantine Hcl	12	suppressed
Nitroglycerin	Nitroglycerin	12	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	12	suppressed
Sertraline Hcl	Sertraline Hcl	12	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	12	suppressed
Synthroid	Levothyroxine Sodium	12	suppressed
Dabigatran Etexilate	Dabigatran Etexilate Mesylate	11	suppressed
Glimepiride	Glimepiride	11	suppressed
Olanzapine	Olanzapine	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error